Pfizer announced that the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) has voted to recommend the following regarding a new dosing schedule:
- For persons at increased risk for meningococcal disease and for use during serogroup B outbreaks, 3 doses of Trumenba should be administered at 0, 1–2, and 6 months
- When given to healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of Trumenba should be administered at 0 and 6 months
- If the second dose is given at an interval of <6 months, a third dose should be given at least 6 months after the first dose
The ACIP recommendation allows flexible vaccination dosing intervals based on the patient’s risk of exposure to meningococcal group B disease. In 2015, the CDC’s ACIP recommended serogroup B meningococcal vaccination for certain patients aged ≥10 years at increased risk for meningococcal disease and recommended that a MenB vaccine series may be given to adolescents and young adults aged 16–23 years (preferred 16–18 years) for short-term protection against most strains of MenB disease.
Trumenba (meningococcal group B vaccine) is a suspension composed of two recombinant lipidated factor H binding protein (fHBP) variants from N. meningitidis serogroup B, one from fHBP subfamily A and one from subfamily B.
Trumenba was granted accelerated approval by the Food and Drug Administration (FDA) in October 2014 for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in patients aged 10–25 years. In April 2016, the FDA approved a revised dosing schedule based on data from Phase 3 trials. It is currently approved to be administered as:
- 3-Dose Schedule: Administer a dose (0.5mL) at 0, 1–2, and 6 months; or
- 2-Dose Schedule: Administer a dose (0.5mL) at 0 and 6 months
This recommendation will be forwarded to the director of the CDC and U.S. Department of HHS for review and approval.
For more information call (800) 438-1985 or visit Trumenba.com.